Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting - Seite 2

• “Binocular Visual Outcomes and Defocus Curve of Bilaterally Implanted Novel Trifocal Intraocular Lens*: A Prospective, Multicenter US study.” Shultz et al.
• “Estimation of Visual Benefit with IC-8 in Keratoconus Patients.” Klyce et al.
• “Initial Results Using Small Aperture Optics IOL in Patients with or without Prior Ocular Surgery, Corneal Scarring or Irregular Astigmatism.” Shultz et al.
• “Outcomes of LASIK Performed Using the Updated Laser Ablation Algorithm for the Correction of Myopia and Myopic Astigmatism.” Chu et al.

Featured Educational Events

Friday, April 5

• “Rethinking Dry Eye Disease: A Contemporary Approach to a Complex Condition”
  7:15-9:15 p.m. ET at Davio's Seaport (26 Fan Pier, Boston)
  The program will feature the dynamic duo of Laura Periman, M.D., and Darrell White, M.D., who will discuss MIEBO and XIIDRA (lifitegrast ophthalmic solution) 5%.

Saturday, April 6

• “Refractive Redefined: TENEO, the New FDA Approved Excimer Laser”
  3:00-3:50 p.m. ET in the at the Boston Convention & Exhibit Center (415 Summer Street, Boston; ASCRS Tap Room)
  Join George Waring IV, M.D., to learn more about the accuracy, efficiency and usability advantages of TENEO, the first excimer laser platform approved in nearly two decades.

• “Innovations in DED and Novel Cataract Surgery Technologies”
  6:30-8:00 p.m. ET at the Omni Boston at the Seaport (450 Summer Street, Boston; Momentum Ballroom, Level 5)
  Join moderator Eric Donnenfeld, M.D., along with presenters Marjin Farid, M.D., Ravi Patel, M.D., and Karl Stonecipher, M.D., to learn more about the benefits of and differences between MIEBO and XIIDRA, as well as the benefits of using the new enVista Aspire lens for doctors and their patients.

Sunday, April 7

• Innovator’s Session
  Featuring Andrew Stewart, President, Global Pharmaceuticals and International Consumer
  10:00am—11:30am, ASCRS Main Stage
  *enVista Envy is pending PMA approval and is not approved for sale in the United States or its territories

###

Important Safety Information for MIEBO

INDICATION
MIEBO (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.

IMPORTANT SAFETY INFORMATION

• Patients should remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting.
• It is important for patients to use MIEBO exactly as prescribed.
• It is not known if MIEBO is safe and effective in children under the age of 18.
• The most common eye side effect seen in studies was blurred vision (1% to 3 % of patients reported blurred vision and eye redness).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.